RGIN (RGIN) Stock Price & Analysis
RGIN (RGIN) rose 0.00% to USD 0 as of June 10, 2026 at 14:07 UTC, according to Nexqual real-time market data.
RGIN last closed at USD 0; the session ranged USD 0–0 on volume of 99,100 shares. Market capitalization is $15,348, with a 52-week range of USD 0–0.75 (PNK). Source: Nexqual, June 10, 2026 at 14:07 UTC.
Key Statistics (as of June 10, 2026 at 14:07 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0.75 |
| Volume | 99,100 shares |
| Market Cap | $15,348 |
| Exchange | PNK |
Technical Analysis (RGIN)
Nexqual's technical model rates RGIN "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 14:07 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (RGIN)
Wall Street analysts rate RGIN "None", per Nexqual as of June 10, 2026 at 14:07 UTC.
| Consensus Rating | None |
|---|
Earnings (RGIN)
Source: Nexqual, June 10, 2026 at 14:07 UTC.
Financials & Fundamentals (RGIN)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.66 |
| Total Cash | $11.86M |
| Total Debt | $642,918 |
| Free Cash Flow | $12.18M |
Source: Nexqual, June 10, 2026 at 14:07 UTC.
Financial Health Score (RGIN)
Nexqual rates RGIN's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 14:07 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — $12M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$700K |
| Efficiency | Mixed — No data |
Ownership (RGIN)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.05% |
| Shares Outstanding | 153.48M |
Source: Nexqual, June 10, 2026 at 14:07 UTC.
Leadership (RGIN)
RGIN is led by Randall E. McCoy (age 76), Chairman, CEO & President, per Nexqual as of June 10, 2026 at 14:07 UTC.
| Chairman, CEO & President | Randall E. McCoy (age 76) |
|---|---|
| CFO & Director | John J. Weber (age 75) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| QMDT | QUICK-MED TECHNOLOGIES INC | USD 0 | ▲ 0% |
| RGRX | REGENERX BIOPHARMACEUTICALS | USD 0 | ▲ 0% |
| MRES | Institute of Biomedical Researc | USD 0 | ▼ 6.67% |
| PFND | PATHFINDER CELL THERAPY INC | USD 0 | ▲ 0% |
| NPHC | Nutra Pharma Corp. | USD 0 | ▲ 50% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 14:07 UTC. This page is informational and not investment advice.